In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Circulating microRNAs as selective markers of anthracyclines-based therapies in breast cancer patients

Session Poster Session 5

Speaker Sonia Gioffre'

Event : ESC Congress 2018

  • Topic : basic science
  • Sub-topic : Basic Science - Cardiac Diseases: Biomarkers
  • Session type : Poster Session

Authors : S Gioffre' (Milan,IT), M Chiesa (Milan,IT), I Alfieri (Milan,IT), S Masson (Milan,IT), R Latini (Milan,IT), MT Sandri (Milan,IT), D Cardinale (Milan,IT), G Pompilio (Milan,IT), GI Colombo (Milan,IT), Y D'alessandra (Milan,IT)

Authors:
S. Gioffre'1 , M. Chiesa1 , I. Alfieri1 , S. Masson2 , R. Latini2 , M.T. Sandri1 , D. Cardinale1 , G. Pompilio1 , G.I. Colombo1 , Y. D'Alessandra1 , 1Cardiology Center Monzino IRCCS - Milan - Italy , 2The Mario Negri Institute for Pharmacological Research - Milan - Italy ,

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 996

Background: The main adverse effect of Anthracyclines, which are highly effective anti-neoplastic drugs, is their cardiotoxicity, leading to progressive heart dysfunction. Assessment of cardiac impairment is usually accomplished by echocardiography, while evaluation of current circulating biomarkers can only give an indication of either initial tissue damage (cardiac troponins) or overt heart failure (natriuretic peptides). Thus, a new class of early diagnostic biomarkers is needed to help assess a possible future dysfunction onset. Recently, circulating microRNAs (miRNAs), small non-coding RNAs with regulatory functions, have been proposed as biomarkers of cardiovascular disease.

Purpose: The aim of this work was the identification of plasma miRNAs that may serve as early prediction tools of anthracycline-induced cardiotoxicity in breast cancer patients receiving either doxorubicin (dox) or epirubicin (epi) treatment.

Methods: Ninety-four female patients with breast cancer treated with anthracyclines were enrolled in this study. In particular, 37 patients received doxorubicin and 57 epirubicin. Subjects were stratified as cases (dox n=20, epi n=12) and controls (dox n=17, epi n=45) based on the presence or absence of an increase in troponin plasma levels, respectively, at any time during or following treatment. Blood was collected at three time points: baseline (before treatment, T0), short follow-up (one month after last infusion, T1), and long follow-up (three months after last infusion, T2). RNA-sequencing was conducted on plasma samples from four randomly selected 6 cases and 6 controls (T0, T1, T2), in order to identify differentially expressed miRNAs. Validation of miRNAs of interest was conducted on all samples by RT-qPCR using TaqMan based single miRNA assays. Statistical analysis was conducted using multiple comparisons test (e.g. two-way ANOVA) as appropriate.

Results: Our data showed an anthracycline-induced modulation for 4 miRNAs: miR-34a, miR-122, miR-376c-3p, and miR-499a-5p. Among them, the first three presented a significant up-regulation at every time points vs. T0, regardless of the administered drug (p<0.05). Interestingly, when focusing on the T0, miR-122 and miR-499a-5p showed (see figure) a higher expression in cases vs. control only in the doxorubicin groups (p<0.05). Differently, no epirubicin-specific miRNA modulation was observed at any time.

Conclusions: This is the first study indicating the potential of specific circulating miRNAs as prediction markers of doxorubicin-induced cardiotoxicity. Although no similar results were obtained for epirubicin, these findings could pave the way to the future identification of miRNAs-based specific diagnostic signatures of cardiotoxicity in anthracycline-based therapies.

Doxorubicin regulated miRNAs at T0

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are